valsartan + atorvastatin + aspirin

This fixed-dose combination (FDC) therapy, often referred to as a cardiovascular polypill, integrates three distinct pharmacological agents to address multiple risk factors for cardiovascular disease. **Valsartan** is an angiotensin II receptor blocker (ARB) that lowers blood pressure by selectively blocking the AT1 receptor, thereby preventing vasoconstriction and aldosterone secretion. **Atorvastatin** is a lipid-modifying HMG-CoA reductase inhibitor that reduces LDL cholesterol and triglycerides while increasing HDL cholesterol through the inhibition of hepatic cholesterol synthesis. **Aspirin** acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1), reducing the production of thromboxane A2 and subsequent platelet aggregation. This combination is primarily indicated for the secondary prevention of cardiovascular events in patients with concurrent hypertension and hypercholesterolemia, aiming to improve long-term medication adherence through regimen simplification.

Brand names

Trinocard

Other names

VAA